"The Food and Drug Administration's top vaccine advisory committee voted unanimously today to recommend Moderna's mRNA influenza vaccine, mFlusiva, for adults 50 and over. This was its first time reviewing a new vaccine application since 2023."
www.npr.org/2026/06/18/n...
www.npr.org
All nine members of the committee unanimously voted to recommend Moderna's new mRNA influenza vaccine for adults 50 and over.